{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:00:26Z","timestamp":1792425626172,"version":"4.5.0"},"reference-count":29,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0782-y","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:05:56Z","timestamp":1573124756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma"],"prefix":"10.1136","volume":"7","author":[{"given":"Marieke J.","family":"Krimphove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl H.","family":"Tully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart R.","family":"Lipsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Kilbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-9276","authenticated-orcid":false,"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"782_CR1","doi-asserted-by":"crossref","unstructured":"Lowe GC, Saavedra A, Reed KB, Velazquez AI, Dronca RS, Markovic SN, et al. Increasing incidence of melanoma among middle-aged adults: an epidemiologic study in Olmsted County, Minnesota Mayo Clinic Proceed 2014;89(1):52\u201359. PubMed PMID: 24388022. Pubmed Central PMCID: PMC4389734. Epub 2014\/01\/07. eng.","DOI":"10.1016\/j.mayocp.2013.09.014"},{"key":"782_CR2","doi-asserted-by":"crossref","unstructured":"Corrie P, Hategan M, Fife K, Parkinson C. Management of melanoma. Br Med Bull 2014;111(1):149\u2013162. PubMed PMID: 25190764. Epub 2014\/09\/06. eng.","DOI":"10.1093\/bmb\/ldu019"},{"key":"782_CR3","doi-asserted-by":"crossref","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet (London, England). 2018;392(10151):971\u2013984. PubMed PMID: 30238891. Epub 2018\/09\/22. eng.","DOI":"10.1016\/S0140-6736(18)31559-9"},{"key":"782_CR4","doi-asserted-by":"crossref","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science (New York, NY). 2015;348(6230):56\u201361. PubMed PMID: 25838373. Epub 2015\/04\/04. eng.","DOI":"10.1126\/science.aaa8172"},{"key":"782_CR5","doi-asserted-by":"crossref","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711\u2013723. PubMed PMID: 20525992. Pubmed Central PMCID: PMC3549297. Epub 2010\/06\/08. eng.","DOI":"10.1056\/NEJMoa1003466"},{"key":"782_CR6","unstructured":"Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol 2018 6. PubMed PMID: 30191256. Epub 2018\/09\/08. eng."},{"key":"782_CR7","doi-asserted-by":"crossref","unstructured":"Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol 2013;20(6):1759\u20131765. PubMed PMID: 23475400. Epub 2013\/03\/12. eng.","DOI":"10.1245\/s10434-013-2901-1"},{"key":"782_CR8","unstructured":"Agriculture USDo. Rural-urban continuum codes 2013 [June 2, 2019]. Available from: https:\/\/www.ers.usda.gov\/data-products\/rural-urban-continuum-codes ."},{"key":"782_CR9","doi-asserted-by":"crossref","unstructured":"Zettervall SL, Schermerhorn ML, Soden PA, McCallum JC, Shean KE, Deery SE, et al. The effect of surgeon and hospital volume on mortality after open and endovascular repair of abdominal aortic aneurysms. J Vasc Surg 2017;65(3):626\u2013634. PubMed PMID: 27988158. Pubmed Central PMCID: PMC5329005. Epub 2016\/12\/19. eng.","DOI":"10.1016\/j.jvs.2016.09.036"},{"key":"782_CR10","doi-asserted-by":"crossref","unstructured":"Davis KF, Hohmann SF, Doukky R, Levine D, Johnson T. The Impact of Hospital and Surgeon Volume on In-Hospital Mortality of Ventricular Assist Device Recipients. J Cardiac Failure. 2016 2016\/03\/01\/;22(3):226\u2013231.","DOI":"10.1016\/j.cardfail.2015.10.012"},{"key":"782_CR11","doi-asserted-by":"crossref","unstructured":"Rosen JE, Hancock JG, Kim AW, Detterbeck FC, Boffa DJ. Predictors of mortality after surgical management of lung cancer in the National Cancer Database. Ann Thorac Surg 2014;98(6):1953\u20131960. PubMed PMID: 25443003. Epub 2014\/12\/03. eng.","DOI":"10.1016\/j.athoracsur.2014.07.007"},{"key":"782_CR12","doi-asserted-by":"crossref","unstructured":"Cole AP, Trinh QD. Secondary data analysis: techniques for comparing interventions and their limitations. Curr Opin Urol 2017;27(4):354\u2013359. PubMed PMID: 28570290. Epub 2017\/06\/02. eng.","DOI":"10.1097\/MOU.0000000000000407"},{"key":"782_CR13","doi-asserted-by":"crossref","unstructured":"Donner A, Donald A. Analysis of data arising from a stratified design with the cluster as unit of randomization. Stat Med 1987;6(1):43\u201352. PubMed PMID: 3576016. Epub 1987\/01\/01. eng.","DOI":"10.1002\/sim.4780060106"},{"key":"782_CR14","doi-asserted-by":"crossref","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18(9):1182\u20131191. PubMed PMID: 28734759. Pubmed Central PMCID: PMC6207072. Epub 2017\/07\/25. eng.","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"782_CR15","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277\u20131290. PubMed PMID: 29562145. Pubmed Central PMCID: PMC5972549. Epub 2018\/03\/22. eng.","DOI":"10.1056\/NEJMoa1712126"},{"key":"782_CR16","doi-asserted-by":"crossref","unstructured":"Buja A, Sartor G, Scioni M, Vecchiato A, Bolzan M, Rebba V, et al. Estimation of direct melanoma-related costs by disease stage and by phase of diagnosis and treatment according to clinical guidelines. Acta Derm Venereol 2018;98(2):218\u2013224. PubMed PMID: 29110018. Epub 2017\/11\/08. eng.","DOI":"10.2340\/00015555-2830"},{"key":"782_CR17","doi-asserted-by":"crossref","unstructured":"Carlaw KR, Woo HH. Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016. Prostate International 2017;5(4):130\u2013134. PubMed PMID: 29188198. Pubmed Central PMCID: PMC5693456. Epub 2017\/12\/01. eng.","DOI":"10.1016\/j.prnil.2017.04.005"},{"key":"782_CR18","doi-asserted-by":"crossref","unstructured":"Francke AL, Smit MC, de Veer AJ, Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Informatics Decision Making 2008;8:38. PubMed PMID: 18789150. Pubmed Central PMCID: PMC2551591. Epub 2008\/09\/16. eng.","DOI":"10.1186\/1472-6947-8-38"},{"key":"782_CR19","doi-asserted-by":"crossref","unstructured":"Keating NL, Huskamp HA, Schrag D, McWilliams JM, McNeil BJ, Landon BE, et al. Diffusion of Bevacizumab across oncology practices: an observational study. Med Care 2018;56(1):69\u201377. PubMed PMID: 29135615. Pubmed Central PMCID: PMC5726588. Epub 2017\/11\/15. eng.","DOI":"10.1097\/MLR.0000000000000840"},{"key":"782_CR20","unstructured":"Heins MJ, de Jong JD, Spronk I, Ho VKY, Brink M, Korevaar JC. Adherence to cancer treatment guidelines: influence of general and cancer-specific guideline characteristics. Eur J Pub Health 2017;27(4):616\u2013620. PubMed PMID: 28013246 . Epub 2016\/12\/26. eng."},{"key":"782_CR21","doi-asserted-by":"crossref","unstructured":"Champer M, Huang Y, Hou JY, Tergas AI, Burke WM, Hillyer GC, et al. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Gynecol Oncol 2018;148(1):19\u201327. PubMed PMID: 29153542. Pubmed Central PMCID: PMC5756507. Epub 2017\/11\/21. eng.","DOI":"10.1016\/j.ygyno.2017.11.008"},{"key":"782_CR22","doi-asserted-by":"crossref","unstructured":"Erickson Foster J, Velasco JM, Hieken TJ. Adverse outcomes associated with noncompliance with melanoma treatment guidelines. Ann Surg Oncol 2008;15(9):2395\u20132402. PubMed PMID: 18600380 . Epub 2008\/07\/05. eng.","DOI":"10.1245\/s10434-008-0021-0"},{"key":"782_CR23","doi-asserted-by":"crossref","unstructured":"Rossi CR, Vecchiato A, Mastrangelo G, Montesco MC, Russano F, Mocellin S, et al. Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). Ann Oncol 2013;24(6):1685\u20131691. PubMed PMID: 23446092. Epub 2013\/03\/01. eng.","DOI":"10.1093\/annonc\/mdt031"},{"key":"782_CR24","unstructured":"Miranda Poma J, Ostios Garcia L, Villamayor Sanchez J, D'Errico G. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events. Allergol Immunopathol 2018 5. PubMed PMID: 29983240. Epub 2018\/07\/10. eng."},{"key":"782_CR25","doi-asserted-by":"crossref","unstructured":"Stokes SM, Wakeam E, Swords DS, Stringham JR, Varghese TK, Jr. Impact of insurance status on receipt of definitive surgical therapy and posttreatment outcomes in early stage lung cancer. Surgery 2018 Dec;164(6):1287\u20131293. PubMed PMID: 30170821. Epub 2018\/09\/02. eng.","DOI":"10.1016\/j.surg.2018.07.020"},{"key":"782_CR26","doi-asserted-by":"crossref","unstructured":"Grant SR, Walker GV, Koshy M, Shaitelman SF, Klopp AH, Frank SJ, et al. Impact of insurance status on radiation treatment modality selection among potential candidates for prostate, breast, or gynecologic brachytherapy. Int J Radiat Oncol Biol Phys 2015;93(5):968\u2013975. PubMed PMID: 26452570. Epub 2015\/10\/11. eng.","DOI":"10.1016\/j.ijrobp.2015.08.036"},{"key":"782_CR27","doi-asserted-by":"crossref","unstructured":"Sitenga JL, Aird G, Ahmed A, Walters R, Silberstein PT. Socioeconomic status and survival for patients with melanoma in the United States: an NCDB analysis. Int J Dermatol 2018;57(10):1149\u20131156. PubMed PMID: 29736922. Epub 2018\/05\/08. eng.","DOI":"10.1111\/ijd.14026"},{"key":"782_CR28","doi-asserted-by":"crossref","unstructured":"Williams GR, Mackenzie A, Magnuson A, Olin R, Chapman A, Mohile S, et al. Comorbidity in older adults with cancer. J Geriatric Oncol 2016;7(4):249\u2013257. PubMed PMID: 26725537. Pubmed Central PMCID: PMC4917479. Epub 2016\/01\/05. eng.","DOI":"10.1016\/j.jgo.2015.12.002"},{"issue":"20","key":"782_CR29","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1001\/jama.280.20.1747","volume":"280","author":"CB Begg","year":"1998","unstructured":"Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998;280(20):1747\u201351.","journal-title":"JAMA"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0782-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T21:59:32Z","timestamp":1664834372000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0782-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0782-y","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Before conducting the study, we obtained a review board waiver from our institution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Quoc-Dien Trinh reports honoraria from Astellas, Bayer and Janssen and Intuitive Surgical. Adam S Kibel reports consulting fees from Sanofi, Dendreon, Tokai, and Profound. Toni K Choueiri reports institutional and personal research support from AstraZeneca, Alexion, Bayer, Bristol Myers-Squibb\/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi\/Aventis, Takeda. Toni K. Choueiri reports honoraria from AstraZeneca, Alexion, Sanofi\/Aventis, Bayer, Bristol Myers-Squibb\/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc. (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics, Lilly. Toni K. Choueiri reports consulting or advisory role with AstraZeneca, Alexion, Sanofi\/Aventis, Bayer, Bristol Myers-Squibb\/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Lilly, Ipsen, Up-to-Date, NCCN, Analysis Group. Toni K. Choueiri reports no speaker\u2019s bureau, no leadership or employment in for-profit companies. Other present or past leadership roles of Toni K. Choueiri: Director of GU Oncology Division at Dana-Farber and past President of medical Staff at Dana-Farber, member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee. Additionally, Toni K. Choueiri reports no patents, royalties or other intellectual properties. He reports travel, accommodations, expenses, in relation to consulting, advisory roles, or honoraria. His medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies. Furthermore, the institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or\/and royalties potentially involved in research around the subject matter.Patrick A. Ott reports consulting or advisory role with Bristol-Myers Squibb, Merck, Pfizer, Novartis, Genentech, CytomX, Array, Celldex, Neon Therapeutics as well as research funding from Bristol-Myers Squibb, Merck, AstraZeneca\/Medimmune, Celldex, CytomX, Genentech, Neon Therapeutics, ARMO Biosciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}